JPMorgan Reinstates Alnylam Pharmaceuticals (ALNY) at Overweight
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $290.07 +1.28%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 23
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 23
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Overweight rating and a price target of $420.00.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $294.30 yesterday.
You May Also Be Interested In
- Lake Street Starts Vivani Medical, Inc. (VANI) at Buy
- Cantor Fitzgerald Starts Factorial Energy (FAC) at Overweight
- Cantor Fitzgerald Starts Quince Therapeutics Inc. (QNCX) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
